Please login to the form below

Not currently logged in
Email:
Password:

chronic cough

This page shows the latest chronic cough news and features for those working in and with pharma, biotech and healthcare.

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’ s chronic cough drug clears mid-stage trial. MK-7264 reduces coughs per hour by 37%. ... P2X3 receptors are thought to become over-activated in chronic cough, playing a role in the hyper-sensitisation of neurons in airways that

Latest news

  • Merck buys cough drug developer Afferent for $1.25bn Merck buys cough drug developer Afferent for $1.25bn

    Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline. ... In a statement Merck's R&F head Roger Perlmutter said chronic cough represents "an area of significant unmet

  • BMS takes option to buy fibrosis firm Galecto BMS takes option to buy fibrosis firm Galecto

    It takes the form of a progressive scarring of the lungs, leading to shortness of breath, cough and - in extreme cases - can lead to fatal complications such as heart failure. ... Genoa Pharmaceuticals has an inhaled version of pirfenidone in phase III

  • Pharma firms open up drug libraries to UK researchers Pharma firms open up drug libraries to UK researchers

    For example, clinical trials are now underway in Manchester to see whether an AZ drug designed originally to treat gastro-oesophageal reflux disease can be used to treat chronic cough.

  • GSK wins US approval for Seretide successor Breo Ellipta GSK wins US approval for Seretide successor Breo Ellipta

    GlaxoSmithKline's new long-term, once-daily, maintenance therapy for chronic obstructive pulmonary disease (COPD) has been approved in the US. ... COPD, whose symptoms can include chest tightness, chronic cough and excessive phlegm, worsens over time and

  • Making the switch to OTC Making the switch to OTC

    We believe that patients should be the primary target of pharma customer loyalty strategies given the significant value of long-term relationships, particularly for patients suffering from chronic diseases. ... worthwhile. Building customer loyalty

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    AF-219, a selective, non-narcotic, oral P2X3 antagonist, is currently in a phase 2b trial for the treatment of refractory, chronic cough and in a phase 2 trial in idiopathic ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics